This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Groot, J.W. B. Articles by Plukker, J.Th. M. Search for Related Content PubMed PubMed Citation Articles by de Groot, J.W. B. Articles by Plukker, J.Th. M.

Impact of ¹⁸F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Biochemical Evidence of Recurrent or Residual Medullary Thyroid Cancer

From the Departments of Surgical Oncology (JWBdeG, TK, JThMP) and Endocrinology (ThPL) and the Nuclear Medicine/PET Center (PLJ), University Hospital, Groningen, The Netherlands.

Correspondence: Address correspondence and reprint requests to: J. Th. M. Plukker, MD, PhD, Department of Surgical Oncology, University Hospital Groningen, P.O. Box 30001, 9700 RB Groningen, the Netherlands; Fax: 31-50-3614873; E-mail: j.t.m.plukker{at}chir.azg.nl

Background: Conventional imaging such as with ^99mTc(V)dimercaptosunnic acid (DMSA), ¹¹¹In-octreotide scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI) rarely localizes occult medullary thyroid cancer (MTC). The role of ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is not well defined. The aim of this study was to examine the usefulness of postoperative FDG-PET in localizing MTC metastases.

Methods: FDG-PET was performed in 26 patients with elevated serum tumor markers after total thyroidectomy with central compartment dissection and additional neck dissection on indication. Patient- and lesion-based results were compared with the findings of conventional nuclear imaging and validated by morphological imaging (CT, MRI, ultrasonography), including bone scintigraphy and pathology when possible. Clinical impact was evaluated.

Results: FDG-PET detected foci in 50% of patients with lesion-based sensitivity of 96%. ¹¹¹In-octreotide detected foci in 19% with sensitivity of 41%, and ^99mTc(V)DMSA scintigraphy and morphological imaging detected foci in 21% and 40%, respectively, with sensitivity of 57% and 87%. No lesions were found in 11 patients (42%). Positive FDG-PET findings led to surgical intervention in nine patients (35%). They all underwent surgery for removal of residual tumor or metastases. One patient achieved disease-free status. In all patients who underwent surgery, serum calcitonin levels were reduced by an average of 58 ± 31%.

Conclusions: For detection of occult MTC lesions, FDG-PET is superior to conventional nuclear imaging and is the best detection method yet available. FDG-PET in postoperative follow-up has clinical value and may be used for guiding reoperation and additional morphological imaging preoperatively.

Key Words: FDG-PET • Medullary thyroid cancer • Metastases

This article has been cited by other articles:

				A Faggiano, F Grimaldi, L Pezzullo, M G Chiofalo, C Caraco, N Mozzillo, G Angeletti, F Santeusanio, G Lombardi, A Colao, et al. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer Endocr. Relat. Cancer, March 1, 2009; 16(1): 225 - 231. [Abstract] [Full Text] [PDF]

				K. P. Koopmans, J. W. B. de Groot, J. T.M. Plukker, E. G.E. de Vries, I. P. Kema, W. J. Sluiter, P. L. Jager, and T. P. Links 18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation J. Nucl. Med., April 1, 2008; 49(4): 524 - 531. [Abstract] [Full Text] [PDF]

				A. Oudoux, P.-Y. Salaun, C. Bournaud, L. Campion, C. Ansquer, C. Rousseau, S. Bardet, F. Borson-Chazot, J.-P. Vuillez, A. Murat, et al. Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4590 - 4597. [Abstract] [Full Text] [PDF]

				A. L. Giraudet, D. Vanel, S. Leboulleux, A. Auperin, C. Dromain, L. Chami, N. Ny Tovo, J. Lumbroso, N. Lassau, G. Bonniaud, et al. Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4185 - 4190. [Abstract] [Full Text] [PDF]

				C. M. Intenzo, S. Jabbour, H. C. Lin, J. L. Miller, S. M. Kim, D. M. Capuzzi, and E. P. Mitchell Scintigraphic Imaging of Body Neuroendocrine Tumors RadioGraphics, September 1, 2007; 27(5): 1355 - 1369. [Abstract] [Full Text] [PDF]

				S. C. Ong, H. Schoder, S. G. Patel, I. M. Tabangay-Lim, I. Doddamane, M. Gonen, A. R. Shaha, R. M. Tuttle, J. P. Shah, and S. M. Larson Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels J. Nucl. Med., April 1, 2007; 48(4): 501 - 507. [Abstract] [Full Text] [PDF]

				C. Are, J. F. Hsu, H. Schoder, J. P. Shah, S. M. Larson, and A. R. Shaha FDG-PET Detected Thyroid Incidentalomas: Need for Further Investigation? Ann. Surg. Oncol., January 1, 2007; 14(1): 239 - 247. [Abstract] [Full Text] [PDF]